Search PubMed⌕ Search

Biomedical subjects

G Jonsson

Publications and source records attributed to G Jonsson.

At least 109 records · Page 6Linked to original sources

Effect of substance P on the 5,7-dihydroxytryptamine induced alteration of the postnatal development of central serotonin neurons.

Systemic treatment with the serotonin neurotoxin 5,7-dihydroxytryptamine [5,7-HT]in the neonatal stage leads to a permanent alteration of the postnatal development of the serotonin neurons in rat brain with denervation of distant nerve terminal projections and hyperinnervation in regions close to the serotonin perikarya. Intracisternal administration of substance P was found to counteract both the denervation and the hyperinnervation, as evaluated by measuring endogenous serotonin levels and [3H]-serotonin uptake in vitro. Furthermore, substance P was found to potentiate the reduction of serotonin induced by tryptophan hydroxylase inhibition with alpha-propyldopacetamide, indicating that substance P can produce an increase in serotonin utilization and turnover. The results suggest that substance P has a degeneration preventing and/or regrowth stimulatory effect on damaged serotonin neurons during ontogeny.

5,7-Dihydroxytryptamine↗

Effect of substance P on neonatally axotomized noradrenaline neurons in rat brain.

Transection (axotomy) of the dorsal tegmental noradrenaline bundle in the neonatal stage leads to a permanent degeneration of noradrenaline nerve terminal projections distal to the lesion (e.g. in the neocortex), while projections proximal to the lesion increase their nerve terminal density (e.g. in the cerebellum). These structural changes are reflected by marked reductions and elevations respectively of the endogenous noradrenaline levels, [3H]-noradrenaline uptake in vitro and nerve density as demonstrated by fluorescence histochemistry. Intracisternal administration of substance P after the transection did not alter these noradrenaline parameters in the neocortex, whereas dose-dependent and significant increases were found in the cerebellum and pons-medulla. The results indicate that substance P may have a growth-stimulatory effect on damaged locus coeruleus noradrenaline neurons in the CNS during ontogeny.

Animals↗

Substance P counteracts neurotoxin damage on norepinephrine neurons in rat brain during ontogeny.

Systemic treatment of newborn rats with the catecholamine neurotoxin 6-hydroxydopamine alters the postnatal development of the central norepinephrine neurons. The changes are permanent and consist of denervation of distant nerve terminal projections (for example, cerebral cortex) and hyperinnervation of terminal areas close to the cell bodies (for example, cerebellum). Intracisternal injection of substance P counteracted both of these alterations. The results indicate that substance P may prevent degeneration of damaged norepinephrine neurons during ontogeny or may have a regrowth stimulatory action on these cells. Substance P might prove of use in the prevention or reduction of other types of neurodegenerative disease.

Animals↗

Evidence for a neurotropic role of noradrenaline neurons in the postnatal development of rat cerebral cortex.

The effects of neonatal administration of the catecholamine neurotoxin 6-hydroxydopamine (6-OHDA; 1-4 doses of 100 mg/kg body weight s.c.) on the postnatal development of pyramidal neurons in several cortical regions of the rat was studied using a Golgi-Cox neuronal impregnation technique. Rats were sacrificed in the adult stage (eight weeks) and the following regions were studied: anterior frontal cortex, posterior frontal cortex (including motor cortex), anterior parietal cortex (including sensory cortex), posterior parieto-occipital cortex and cingulate cortex. Significant alterations were seen in animals which received four doses of 6-OHDA. These alterations can be summarized as follows: (1) a decreased length and branching of basolateral dendrites of pyramidal cells, with loss of dendritic spines, which were found in both the internal pyrimidal layer (layer V) and the external pyramidal layer (layer III), most abundantly in the frontal cortex and cingulate cortex; (2) an increased number of pyramidal cells of layer V with premature apical dendritic termination in layer III rather than the usual termination in layers I and II. This was most abundant in the cingulate cortex; (3) occasional disorientation of pyramidal cell apical dendrites away from the normal vertical plane by 15 or more degrees, seen in frontal, parietal and cingulate cortex; (4) an increased number of pyramidal cells with rounded somatic contours, found in frontal, anterior parietal and cingulate cortex. These phenomena were occasionally seen in normal cortex, but were significantly increased in their occurrence after four doses of 6-OHDA. Such alterations were not significant in rats treated with one or three doses of 6-OHDA. The extent and severity of morphological alterations correlate with reductions in endogenous noradrenaline (NA) in cerebral cortex, which was found to average 50% of control levels after one dose of 6-OHDA, and 80% reduction after three doses, and a 97-98% reduction after four doses, suggesting that the NA denervation must be almost complete to result in readily detectable significant morphological changes in the development of cortical pyramidal cells. No consistent changes in endogenous dopamine (DA) levels were observed, except for an increase in the cingulate cortex. The anatomical alterations in pyramidal cells described in the present study suggest that NA neurons which project into the cerebral cortex have a neurotrophic role in the postnatal development of cortex.

Aging↗

Effects of the noradrenaline neurotoxin DSP4 on the postnatal development of central noradrenaline neurons in the rat.

The effect of the noradrenaline neurotoxin DSP4 on the postnatal development of central noradrenergic neurons in the rat has been investigated using neurochemical techniques. The results demonstrated a preferential effect of DSP4 on the locus coeruleus noradrenergic neuron system without any notable effects on the dopamine and adrenaline neurons and only a minor neurotoxic effect on the serotonin neurons. The effect of DSP4 on the serotonin neurons could be completely prevented by pretreatment with the uptake blocker zimelidine, without affecting the action of DSP4 on noradrenergic neurons. Neonatal DSP4 treatment systemically led to permanent depletions of noradrenaline in the cerebral cortex and spinal cord and marked increases of noradrenaline in the cerebellum and pons-medulla. These effects of DSP4 were dose-dependent and could be blocked by pretreatment with the noradrenaline uptake blocker desipramine. The alterations in endogenous noradrenaline levels were quantitatively similar to changes observed in [3H]noradrenaline uptake in slices in vitro. There were no significant changes of these noradrenergic parameters when analysing the whole CNS after neonatal DSP4 treatment, in spite of marked regional changes in both directions. Administration of DSP4 to rats of different ages produced acutely marked depletions of noradrenaline in all regions including the pons-medulla and the cerebellum at all developmental stages. Marked and permanent depletions of noradrenaline were found in the distant noradrenergic nerve terminal projections after treatment at all ages, whereas increases in noradrenaline levels in the pons-medulla and cerebellum were only observed in rats treated with DSP4 up to the age of 3-5 days, whereas a DSP4 administration in older rats led to substantial and permanent depletions of noradrenaline in both these regions. The results indicate that the alteration of the postnatal development of noradrenergic neurons after treatment of rats up to the age of 3-5 days is mainly related to a 'pruning effect' of DSP4, in which prevention of the development of distant nerve terminal projections causes an increased outgrowth of nerves in collateral systems spared by the neurotoxin. The results indicate that DSP4 may be a useful denervation tool for studying various aspects of noradrenergic neurotransmission of developing locus coeruleus neurons.

Amines↗

Substance P modifies the 6-hydroxydopamine induced alteration of postnatal development of central noradrenaline neurons.

Systemic treatment of new-born rats with the catecholamine neurotoxin 6-hydroxydopamine leads to a permanent and selective alteration of the postnatal development of the central noradrenaline neurons, in particular of the locus coeruleus system. The changes involve a pronounced and permanent degeneration of distant nerve terminal projections (e.g. in the cerebral cortex and spinal cord) and a hyperinnervation of regions close to the noradrenaline perikarya (e.g. in the cerebellum and pons-medulla). Substance P administered intracisternally was found to counteract significantly both the 6-hydroxydopamine-induced denervation and hyperinnervation, as monitored by measuring endogenous noradrenaline levels and [3H]noradrenaline uptake in vitro. The counteracting effect of substance P disclosed a clear dose-response relationship and was most effective when injected on postnatal days one and two, while practically no effects were observed after injection on postnatal days three and four. Substance P treatment alone of new-born rats had no effect on the postnatal development of the regional monoamine levels. Binding studies employing radioligand technique showed substance P treatment to abolish the 6-hydroxydopamine-induced increase in beta-receptor binding in the frontal cortex, suggesting the 'spared' noradrenaline terminals to be functionally active. Substance P was shown to increase the utilization of noradrenaline in the neonatal stage. The results indicate that the counteracting effect of substance P may be due to a prevention of degeneration, growth stimulation and/or trophic influences on central noradrenaline neurons, possibly related to an excitatory effect of substance P on noradrenaline neurons.

Animals↗

Selective (+)-amphetamine neurotoxicity on striatal dopamine nerve terminals in the mouse.

1 Infusion of large doses of (+)-amphetamine continuously for 7 days by means of osmotic minipumps caused a long-lasting reduction of endogenous dopamine levels, dopamine nerve terminals demonstrated histochemically and [3H]-noradrenaline uptake in vitro in the striatum of mice. 2 The effect was dose-dependent, fully developed after 4 days and selective for striatal dopamine up to a dose of (+)-amphetamine of 25 microgram/h. Higher doses, which produced increased mortality, also affected dopamine levels in the olfactory tubercle as well as noradrenaline in several regions. 3 Fluorescence histochemical studies using the Falck-Hillarp technique disclosed catecholamine accumulations in the striatum after (+)-amphetamine; a sign of neurotoxic damage. No effects on the dopamine cell bodies were noted. There were also no indications of neurotoxic damage to noradrenaline or 5-hydroxytryptamine neurones induced by (+)-amphetamine. 4 Large doses of (-)-amphetamine were without effect, demonstrating that the long-lasting impairment of transmitter uptake-storage mechanism in striatal dopamine nerve terminals is selective for (+)-amphetamine. 5 There was a slow gradual recovery of endogenous dopamine and [3H]-noradrenaline uptake in the striatum with time, which was almost complete 6 months after the (+)-amphetamine administration. 6 The results give further evidence for the view that (+)-amphetamine in large doses can have a selective neurotoxic action on a vulnerable population of a dopamine nerve terminals in the striatum. The results suggest in addition that there is a slow regrowth and regeneration with time of damaged dopamine nerve terminals.

Animals↗

Blood-brain barrier permeability and immobilization stress.

The regional capacity of the blood-brain barrier (BBB) has been investigated in rat brain during normal conditions and after acute immobilization (IMO). The BBB function was monitored by fluorescence microscopical localization of systemically administered vital dye (trypan blue) and by studying the ability of the brain capillaries to decarboxylate and trap injected L-DOPA. The results demonstrated clear signs of dye penetration into the parenchyma of certain brain regions (area preoptica, some hypothalamic nuclei, area ventralis tegmenti and ventral part of the pons and medulla oblongata) in addition to the areas known to be 'outside the BBB' (the circumventricular organ). There was an an apparent increase in dye penetration in these regions after IMO, most pronounced in the reticular formation of the brain stem. In the mesencephalic reticular formation ruptures of a substantial number of vessels occurred after IMO leading to massive leakage of dye into surrounding brain parenchyma. The main finding after L-DOPA administration was indications of a more efficient decarboxylation and trapping of L-DOPA in most brain regions after IMO. The findings of dye penetration in certain brain regions, which are known to be involved in autonomic regulation, may reflect possible ways of chemical communication between the circulation and neuronal structures in these regions and/or possibly constitute the basis for inactivation processes for transport of substances outwards from the brain as well as potential loci for adverse effects and development of pathological conditions.

Animals↗

Effects of morphine on the 6-hydroxydopamine induced changes of the postnatal development of central noradrenaline neurons.

Neonatal treatment with the catecholamine neurotoxin 6-hydroxydopamine (6-OH-DA) leads to permanent noradrenaline (NA) denervations of distant projections (e.g. in the neocortex) with a concomitant NA hyperinnervation in regions close to the perikarya (e.g. in the cerebellum) a "pruning effect' mainly affecting the locus coeruleus NA neuron system. Morphine administration after 6-OH-DA produced a significant potentiation of the 6-OH-DA-induced NA depletion in the olfactory bulb, spinal cord, frontal and occipital cortex, with a tendency for NA to increase in the mesencephalon, pons-medulla and cerebellum, when analysed in the adult stage. Morphine treatment alone had no effects on the NA levels in any region studied. Morphine was found to counteract the NA depletion induced by tyrosine hydroxylase inhibition in neonate rats, indicating that morphine reduces NA turnover. The present results are compatible with the view that morphine potentiates the 6-OH-DA-induced degeneration of NA nerve terminals, possibly related to the inhibitory action on NA neurons.

Animals↗

Response of central monoamine neurons following an early neurotoxic lesion.

Systemic treatment with the selective monoamine neurotoxins 6-hydroxydopamine (6-OH-DA), N-(2-chloroethyl)N-ethyl-2-bromobenzylamine (DSP4) or 5,7-dihydroxytryptamine (5,7-HT) in the neonatal stage produces marked and permanent alterations of the postnatal development of central noradrenaline (NA) and 5-hydroxytryptamine (5-HT) neurons. 6-OH-DA and DSP4 act preferentially on NA neurons, in particular on the locus coeruleus system, whereas 5,7-HT acts on 5-HT neurons. The neurotoxin treatment leads to pronounced denervations of distant nerve terminal projections while innervation areas close to the cell bodies become hyperinnervated. The total number of monoamine nerve terminals developed in the CNS after the neurotoxin treatment is approximately unchanged. A surgical lesion of NA and 5-HT axons in the neonatal stage causes similar changes compared to a neonatal neurotoxin treatment. The postsynaptic monoamine receptors appear to develop independently of the presynaptic nerve terminals, although the transmitter availability at the receptors is able to regulate the number of receptors (up and down regulation). The transmitter turnover is increased in terminals spared by the neurotoxin in denervated areas, while decreased in hyperinnervated regions. The alterations in receptor density and transmitter turnover may represent compensatory mechanisms. Substance P has a counteracting effect while morphine has a potentiating effect on the 6-OH-DA-induced NA denervation and hyperinnervation, indicating that the functional state of the neuron may modulate the final outcome of a neonatal 6-OH-DA treatment. The results indicate that the altered development of central monoamine neurons following a neonatal monoamine neurotoxin treatment or axotomy is mainly related to a 'pruning effect', i.e. the prevention of the development of one axonal branch leads to a proliferative growth response in intact branches.

Animals↗

Amphetamine neurotoxicity on dopamine nerve terminals in the caudate nucleus of mice.

Continuous administration of D-amphetamine to mice by osmotic minipumps (placed s.c.) delivering 25 micrograms/h for 7 days led to significant decreases in the endogenous dopamine concentration (-51%) and [3H]noradrenaline uptake (-43%) in vitro in the caudate nucleus. Fluorescence histochemical analysis demonstrated a marked reduction of dopamine fluorescence as well as catecholamine accumulations (sign of neurotoxicity) in the caudate nucleus. No notable effects were noted on the fluorescence morphology of the dopamine cell bodies in the mesencephalon. The dopamine levels were still significantly reduced (-37%) after two months, while the [3H]noradrenaline uptake had at this time-point reached almost normal values. The results are compatible with the view that D-amphetamine can induce acutely a neurodegenerative damage of central dopamine neurons at the level of the nerve terminals in the caudate nucleus with possibilities for regeneration and recovery in the chronic state.

Amphetamine↗

DSP4 (N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine)--a useful denervation tool for central and peripheral noradrenaline neurons.

The effect of N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP4) on monoamine neurons was studied in mice and rats. In mice DSP4 produced acutely a marked reduction of endogenous noradrenaline (NA), [3H]NA uptake and nerve density of the adrenergic nerves in the iris and atrium. Pronounced accumulations of NA were observed in non-terminal axons, which is a degenerative sign, while no changes were found in the NA cell bodies. A marked recovery of all parameters analysed was found as soon as 1 week after DSP4. In the mouse CNS, however, there was a marked and long-lasting NA reduction, especially in the cerebral and cerebellar cortex and spinal cord, leaving dopamine (DA) and serotonin (5-HT) neurons apparently unaffected. Administration of DSP4 to adult rats produced regional changes in the NA levels of the CNS were similar to those observed in the mouse. There were no indications of DSP4 affecting dopamine and adrenaline neurons in rat CNS, although a minor 5-HT depleting effect was noted. DSP4 treatment resulted in an increase in beta-adrenoceptor binding in vitro to homogenates from the cerebral cortex, using [3H]dihydroalprenolol as radioligand. Treatment of newborn rats with DSP4 caused permanent NA disappearance in the cerebral cortex and spinal cord, whereas marked NA increases were found in the pons-medulla and cerebellum. Administration of DSP4 to pregnant rats (gestation day 15) led to a marked and permanent NA depletion in the cerebral cortex and spinal cord in the offspring. The results support the view that DSP4 can produce an acute and relatively selective degeneration of NA nerve terminals in the rat and mouse. The results furthermore indicate that DSP4 (systemically administered) causes a preferential degeneration of NA nerve terminal projections originating from the locus coeruleus in the CNS. Since DSP4 can pass both the blood-brain and blood-placenta barrier and appears to have potent neurotoxic actions on NA neurons, DSP4 may serve as a useful denervation tool for the analysis of NA transmitter functions, particularly in the CNS of both adult and developing animals.

Amines↗

Reversal of noradrenaline denervation-induced increase of beta-adrenoreceptor binding in rat neocortex by noradrenaline infusion.

The effect of intraventricular infusion of (-)-noradrenaline (NA) on beta-receptor binding in vitro to homogenates from 6-hydroxydopamine (6-OH-DA)-denervated and from normal rat cerebral cortex was studied. NA was infused with osmotic minipumps connected to cannulas placed in the right lateral ventricle, delivering 1 or 5 microgram (-)-NA/h continuously for 9 days. One day later the rats were sacrificed and cortical tissue taken for beta-receptor (using [3H]dihydroalprenolol ([3H]DHA) as radioligand) and NA assay. The NA level in the cerebral cortex of 6-OH-DA treated rats was decreased to 70-80% of that of controls. No substantial change in the NA level was observed after infusion of 1 microgram (-)-NA/h, whereas infusion of 5 microgram/h led to a 40-60% increase compared to that of control rats infused with vehicle alone. Infusion of vehicle alone into control rats did not cause any change in [3H]DHA binding, whereas in denervated rats there was a 30-50% increase in [3H]DHA binding compared to that of controls. This increase was completely counteracted by infusion of 1 or 5 microgram (-)-NA/h. Infusion of 1 microgram (-)-NA/h to control rats did not cause any change, while infusion of 5 microgram (-)NA/h led to a significant decrease (-24%) in [3]DHA binding. The present results further support the view that the availability of NA at the receptors controls the number of beta-adrenergic receptors, thereby probably regulating the NA sensitivity of cells with beta-receptors.

Animals↗

5-Methoxyindoles in pineal gland of cow, pig, sheep and rat.

The occurrence and concentration of the four 5-methoxyindoles: 5-methoxtryptamine, 5-methoxytryptophol, 5-methyoxyindole-3-acetic acid and melatonin in the pineal gland of pig, cow, sheep and rat was investigated. The analytical method involved the use of deuterated analogues as internal standards and capillary column gas chromatography - mass spectrometry. The analyses of pineal glands obtained during the morning hours revealed the presence of 5-methoxyindole-3-acetic acid and melatonin in nmoles/g and 5-methyoxytryptophol and 5-methoxytryptamine in pmoles/g amounts in pig, cow and sheep. In Wistar and Sprague-Dawley strain of rat, melatonin was present at a concentration of about 0.5 pmoles/pineal, a level which was elevated more than five times by treatment with a monoamine oxidase inhibitor. 5-Methoxytryptamine was found at a concentration of about 0.03 pmoles/pineal, and was elevated by monoamine oxidase inhibition.

5-Methoxytryptamine↗

Effects of prenatal methylazoxymethanol treatment on the development of central monoamine neurons.

The effects of prenatal treatment with the antimitotic agent methylazoxymethanol (MAM; 25 mg/kg i.v., gestation day 15) on the development of monoamine neurons and their receptors have been investigated by neurochemical techniques. The MAM treatment led to a forebrain microencephaly with an approximately 50% weight reduction of the cerebral cortex and hippocampus, 30% of the striatum while the other CNS regions were reduced by about 5-15%. Endogenous noradrenaline (NA) dopamine (DA) and 5-hydroxytryptamine (5-HT) concentrations in the cerebral cortex and hippocampus were increased by about 100% and to a similar extent for all amines, whereas the total amine content in each brain region analyzed was more or less unchanged after MAM treatment. The DA concentration in the striatum was increased by 40% without any change in the total DA content. The subcellular distribution of NA and DA in the cerebral cortex and striatum was similar in MAM-treated and control rats. The effect of the NA denervation agent DSP4 was identical in MAM-treated and controls, showing very pronounced NA reductions in the cerebral cortex, hippocampus, cerebellum and the spinal cord, while the DA levels in various brain regions were not or only to a minor degree affected. Analysis of [3H]NA and [3H]5-HT uptake in slices from the cerebral cortex in vitro, demonstrated an approximate doubling of the uptake (calculated per weight) for both amines after MAM, while total uptake was not notably changed. MAM treatment also led to a significant reduction of the in vitro binding of various radioligands for monoamine (alpha, beta, 5-HT) receptors. The most pronounced reduction was observed for beta-receptors. Administration of a tyrosine-hydroxylase (alpha-methyl-p-tyrosine) or a tryptophan hydroxylase (alpha-propyldopacetamide) inhibitor led to marked NA/DA and 5-HT reductions after MAM in all regions analyzed, indicating that the monoamine neurons are active in synthesizing and releasing their neurotransmitter. The results suggest that MAM treatment leads to a monoamine hyperinnervation in the atrophic regions without markedly changing the total number of monoamine nerve terminals. All the monoamine nerves appear to develop independent of the formation of the post-synaptic receptors. The results imply that monoamine neurons in the CNS are strictly programmed to produce a certain quantity of nerve terminal arborizations in regions they innervate during the development relatively independent of the effector cells, pointing to a high degree of intrinsic growth regulation.

Animals↗